about
Memantine for schizophreniaThe involvement of N-methyl-D-aspartate receptor (NMDAR) subunit NR1 in the pathophysiology of schizophrenia.Brain in flames - animal models of psychosis: utility and limitationsEffects of N-acetylaspartylglutamate (NAAG) peptidase inhibition on release of glutamate and dopamine in prefrontal cortex and nucleus accumbens in phencyclidine model of schizophreniaLongitudinal assessment of neuronal 3D genomes in mouse prefrontal cortex.Calcium-dependent networks in dopamine-glutamate interaction: the role of postsynaptic scaffolding proteins.Animal models for predicting the efficacy and side effects of antipsychotic drugs.The glutamatergic aspects of schizophrenia molecular pathophysiology: role of the postsynaptic density, and implications for treatmentInvolvement of the Striatal Medium Spiny Neurons of the Direct Pathway in the Motor Stimulant Effects of Phencyclidine.Computational study of NMDA conductance and cortical oscillations in schizophrenia.Glycine reuptake inhibition: a promising therapeutic strategy in the treatment of schizophrenia?MEF2C transcription factor is associated with the genetic and epigenetic risk architecture of schizophrenia and improves cognition in mice.Cortical high gamma network oscillations and connectivity: a translational index for antipsychotics to normalize aberrant neurophysiological activity.PCP-based mice models of schizophrenia: differential behavioral, neurochemical and cellular effects of acute and subchronic treatments.
P2860
Q24202544-7C221651-C987-4FDA-9F6F-286A3D8559DDQ30362017-D1794E16-39DB-42E3-A04E-53F84A455BB4Q35683865-E4462F68-2F00-4190-8116-01C48C1487D3Q36052391-6924FEFA-F039-4B1C-BC8A-B70D71FE2976Q37261031-C7AB4DE1-24B1-4D90-85B2-4BA788986C0DQ38024032-ECEAD791-2BF5-42C1-AAD4-1092189BB9B0Q38165756-A351E4B4-E928-44E9-B0E1-29BE61F06C9CQ38213709-14064837-578E-4F9B-B9B4-6E914C9943E6Q42507075-851C0107-B205-4D5A-8CCB-E346DCCABA23Q42949279-8D0AA1C1-D69C-4C88-8C0C-D5C5F07A8D85Q44604205-15AFFE5E-8DFA-4FB0-85D5-7C8724DBA069Q45051337-4B92442B-3534-4013-8B79-C607A3179B58Q47911078-6D4C1F48-2262-4C8F-994D-485B6FBFA312Q48192793-D69A2318-3C86-4EB0-A92E-0299D45F3452
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Glutamatergic animal models of schizophrenia.
@ast
Glutamatergic animal models of schizophrenia.
@en
Glutamatergic animal models of schizophrenia.
@nl
type
label
Glutamatergic animal models of schizophrenia.
@ast
Glutamatergic animal models of schizophrenia.
@en
Glutamatergic animal models of schizophrenia.
@nl
prefLabel
Glutamatergic animal models of schizophrenia.
@ast
Glutamatergic animal models of schizophrenia.
@en
Glutamatergic animal models of schizophrenia.
@nl
P1476
Glutamatergic animal models of schizophrenia.
@en
P2093
Marguerite Matthews
P304
P356
10.2174/138161212799958576
P577
2012-01-01T00:00:00Z